Tell us who you want to see featured on the list – and why, using the link below. We are counting on you to nominate your collaborators, colleagues and peers.
Should pharma companies transition from developing, manufacturing and pricing “drugs” to promoting “health”?
GDUFA fees for 2020 have been decided – and include a significant drop in the fees for finished dosage facilities.
When it comes to developing cell and gene therapies, you need to keep your eye on the end goal of commercial manufacturing.
Clinical trials need an overhaul – and AI is the solution.
Will the antibiotic apocalypse kill us all?
In times of political and social upheaval, maintaining our links across borders and working closely together is more important than ever.
With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.
Scientific careers are inherently unpredictable, but there are a number of steps we can take to be prepared.
Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.
We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.